Let us know if we're missing any workplace or industry recognition –
EntreMed wants to get in between cancer and the blood vessels that feed it. The biotech pharmaceutical company develops drugs that inhibit angiogenesis, or the growth of new blood vessels. Its lead candidate, ENMD-2076, inhibits aurora kinases which regulate cell division and are linked to several cancers. The company has several other product candidates in its pipeline. EntreMed receives royalties from sales of Thalomid, a multiple myeloma therapy marketed by EntreMed's minority shareholder, Celgene.